Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Oncogene

• Publication date

  2009-02-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2008.432PMID 19060928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

  2009cited by this paper
• NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy

  2008cited by this paper
• Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

  2007cited by this paper
• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  2007influential reference
• Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen1

  2007cited by this paper
• The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers

  2007cited by this paper
• Degradation of HER2 by Cbl-based chimeric ubiquitin ligases.

  2007cited by this paper
• Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

  2007cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression

  2006cited by this paper
• Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

  2006cited by this paper
• An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

  2006influential reference
• Targeting Tyrosine Kinases in Cancer: The Second Wave

  2006cited by this paper
• EGF–ERBB signalling: towards the systems level

  2006cited by this paper
• Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor

  2006cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity against Esophageal Squamous Cell Carcinoma

  2005cited by this paper
• Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.

  2005cited by this paper
• The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.

  2005cited by this paper
• TGFα expression impairs Trastuzumab-induced HER2 downregulation

  2005cited by this paper
• Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity

  2005cited by this paper
• Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

  2005cited by this paper
• Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

  2005cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Herceptin‐induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down‐regulation of ErbB2

  2005cited by this paper
• TGFalpha expression impairs Trastuzumab-induced HER2 downregulation.

  2005cited by this paper
• Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases

  2004cited by this paper
• A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

  2004cited by this paper
• Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)

  2004cited by this paper
• Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)

  2004cited by this paper
• Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

  2004cited by this paper
• Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

  2004cited by this paper
• Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene–Amplified Breast Cancer Cells

  2004cited by this paper
• Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy

  2004cited by this paper
• Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.

  2004cited by this paper
• The Role of ErbB2 Signaling in the Onset of Terminal Differentiation of Oligodendrocytes In Vivo

  2003cited by this paper
• HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice1

  2003cited by this paper
• Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478

  2003cited by this paper
• ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

  2003cited by this paper
• Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

  2002cited by this paper
• Tumour biology: Herceptin acts as an anti-angiogenic cocktail

  2002cited by this paper
• The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

  2001cited by this paper
• Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.

  1999cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site*

  1997cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper
• 2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor.

  1993cited by this paper
• Comparative protein modelling by satisfaction of spatial restraints.

  1993cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

  1983cited by this paper

• Electrochemical platform for in situ metabolic profiling and therapeutic evaluation of triple-negative breast cancer

  2026cites this paper
• Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review.

  2026cites this paper
• Immunotherapy Targeting HER2-positive Breast Cancer

  2025cites this paper
• The Mechanisms and Applications of Endocytosis and Exocytosis in Breast Cancer Therapy

  2025cites this paper
• The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC

  2025cites this paper
• Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial.

  2025cites this paper
• EGFR activation and conformational "convergence": an emerging allosteric model from cancer mutations.

  2025cites this paper
• Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment

  2025cites this paper
• Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial

  2025cites this paper
• Label-Free Longitudinal Imaging of Single Cell Drug Response with a 3D-Printed Cell Culture Platform

  2025cites this paper
• Label-Free Longitudinal Imaging of Single Cell Drug Response with a 3D-Printed Cell Culture Platform.

  2025cites this paper
• Antibody–drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives

  2025cites this paper
• The activity of EGFR CAR-NK and CAR-T cells against EGFR inhibitor-resistant NSCLC and drug-tolerant persister cells.

  2025cites this paper
• Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes

  2025cites this paper
• Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine

  2025cites this paper
• CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells

  2025cites this paper
• TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, rastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis

  2025cites this paper
• Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial

  2024cites this paper
• Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

  2024cites this paper
• Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials

  2024cites this paper
• EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance

  2024cites this paper
• Inhibitory Effects of Alpha-Connexin Carboxyl-Terminal Peptide on Canine Mammary Epithelial Cells: A Study on Benign and Malignant Phenotypes

  2024cites this paper
• Protein tyrosine phosphatase PTPH1 potentiates receptor tyrosine kinase HER2 oncogenesis via a PDZ-coupled and phosphorylation-driven scaffold.

  2024cites this paper
• Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer

  2024cites this paper
• Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy

  2024cites this paper
• Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers

  2024cites this paper
• Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

  2024cites this paper
• Highly Multiplexing, Throughput and Efficient Single‐Cell Protein Analysis with Digital Microfluidics

  2024cites this paper
• Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy.

  2024cites this paper
• The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

  2024cites this paper
• Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics

  2024cites this paper
• Catalysts of Healing: A Symphony of Synthesis and Clinical Artistry in Small-Molecule Agents for Breast Cancer Alleviation

  2024cites this paper
• A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer

  2024cites this paper
• A peptide-centric local stability assay enables proteome-scale identification of the protein targets and binding regions of diverse ligands

  2024cites this paper
• Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death.

  2023cites this paper
• Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines

  2023cites this paper
• Emerging Targeted Therapies for HER2-Positive Breast Cancer

  2023cites this paper
• Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer

  2023cites this paper
• Development of antibody‐drug conjugates in cancer: Overview and prospects

  2023cites this paper
• Privileged Scaffolds in Drug Discovery against Human Epidermal Growth Factor Receptor 2 for Cancer Treatment.

  2023cites this paper
• Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study

  2023cites this paper
• ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.

  2023cites this paper
• Endocytosis in cancer and cancer therapy

  2023cites this paper
• Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase–relevant subgroup with therapeutic prospects

  2023influential citation
• Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer.

  2023cites this paper
• Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?

  2023cites this paper
• miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review

  2023cites this paper
• Antibody-drug conjugates: in search of partners of choice.

  2023cites this paper
• Anticipating changes in the HER2 status of breast tumours with disease progression—towards better treatment decisions in the new era of HER2-low breast cancers

  2023cites this paper
• Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer

  2023cites this paper
• Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine

  2023cites this paper
• CD98 regulates the phosphorylation of HER2 and a bispecific anti‐HER2/CD98 antibody inhibits the growth signal of human breast cancer cells

  2023cites this paper
• Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells

  2023cites this paper
• Synthesis of novel pyrimido[4,5‐b]quinolines as potential anticancer agents and HER2 inhibitors

  2023cites this paper
• HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

  2023cites this paper
• Offsetting Low-Affinity Carbohydrate Binding with Covalency to Engage Sugar-Specific Proteins for Tumor-Immune Proximity Induction

  2023cites this paper
• A Case Report on the Efficacy of Trastuzumab Emtansine in a Patient With Human Epidermal Growth Factor Receptor 2 Exon 20-Mutated Adenocarcinoma of the Lung

  2023cites this paper
• HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks

  2023cites this paper
• Ampk Activation Attenuates Her3 Upregulation And Neuregulin-Mediated Rescue of Cell Proliferation in Her2-Overexpressing Breast Cancer Cell Lines Exposed to Lapatinib.

  2022cites this paper
• Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions

  2022cites this paper
• Flow Cytometry Analysis to Detect Lapatinib-Induced Modulation of Constitutive and IFN-γ-Induced HLA Class I Expression in HER2-Positive Breast Cancer Cells.

  2022cites this paper
• Immunological Landscape of HER-2 Positive Breast Cancer

  2022cites this paper
• Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls

  2022cites this paper
• Resistance to Trastuzumab

  2022cites this paper
• Western Blot Analysis of Lapatinib-Mediated Inhibition of the Epidermal Growth Factor Receptor 2 (HER2) Pathway in Breast Cancer Cells.

  2022cites this paper
• Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer

  2022cites this paper
• Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.

  2022cites this paper
• Evolution of low HER2 expression between early and advanced-stage breast cancer.

  2022cites this paper
• A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells

  2022cites this paper
• Strategies for the treatment of HER2+ advanced breast cancer based on clinical practice in Chinese patients: a roundtable discussion

  2022cites this paper
• Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives

  2022cites this paper
• Phase II Trial of Metronomic Capecitabine and Cyclophosphamide with Lapatinib and Trastuzumab in Patients with HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen

  2022cites this paper
• Designing of kinase hinge binders: A medicinal chemistry perspective

  2022cites this paper
• The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer.

  2022cites this paper
• HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models

  2021cites this paper
• From antibodies to living drugs: Quo vadis cancer immunotherapy?

  2021cites this paper
• Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma

  2021cites this paper
• The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers

  2021cites this paper
• A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants.

  2021cites this paper
• Adenoid cystic carcinoma: A review of clinical features, treatment targets and advancement in improving the immune response to monoclonal antibody therapy.

  2021cites this paper
• Trastuzumab immunogenicity development in patients’ sera and in laboratory animals

  2021cites this paper
• Immunotherapy as a partner for HER2-directed therapies

  2021cites this paper
• Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.

  2021cites this paper
• Identification of Lapatinib Derivatives and Analogs to Control Metastatic Breast Cancer-specific to South Asian Population-a Pharmacogenomic Approach

  2021cites this paper
• Screening of phytochemicals as potential anti-breast cancer agents targeting HER2: an in-silico approach

  2021cites this paper
• Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases

  2021cites this paper
• Immunotherapy in Breast Cancer: When, How, and What Challenges?

  2021cites this paper
• Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

  2021cites this paper
• Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)

  2021cites this paper
• PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer

  2021cites this paper
• Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma

  2021cites this paper
• Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma

  2021cites this paper
• Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

  2021cites this paper
• Ex Vivo Drug Screening Informed Targeted Therapy for Metastatic Parotid Squamous Cell Carcinoma

  2021cites this paper
• Title : Targeting HER 2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel 2 Tyrosine Kinase Inhibitor

  2021cites this paper
• UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells

  2021cites this paper
• Caveolin-1 temporal modulation enhances trastuzumab and trastuzumab-drug conjugate efficacy in heterogeneous gastric cancer

  2021cites this paper
• EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd

  2021cites this paper
• Targeting fibroblast growth factor receptors to combat aggressive ependymoma

  2021cites this paper
• Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

  2020influential citation